OptimizeRx CorporationOPRXNASDAQ
Loading
Year-over-year research & development expense growth
Latest
-100.00%
↓ 1047% vs avg
Percentile
P3
Near historical low
Streak
1 qtr
Consecutive declineDecelerating
Average
10.56%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | -100.00% |
| Q3 2025 | 0.00% |
| Q2 2025 | -100.00% |
| Q1 2025 | 0.00% |
| Q4 2024 | -100.00% |
| Q3 2024 | 28.17% |
| Q2 2024 | 0.00% |
| Q1 2024 | 0.00% |
| Q4 2023 | -100.00% |
| Q3 2023 | 0.00% |
| Q2 2023 | 0.00% |
| Q1 2023 | 0.00% |
| Q4 2022 | 0.00% |
| Q3 2022 | 0.00% |
| Q2 2022 | 0.00% |
| Q1 2022 | 0.00% |
| Q4 2021 | 0.00% |
| Q3 2021 | 0.00% |
| Q2 2021 | 0.00% |
| Q1 2021 | 100.00% |
| Q4 2020 | -208.39% |
| Q3 2020 | -4.77% |
| Q2 2020 | 8.65% |
| Q1 2020 | -65.18% |
| Q4 2019 | 55.10% |
| Q3 2019 | 366.12% |
| Q2 2019 | 1.74% |
| Q1 2019 | -7.49% |
| Q4 2018 | 105.70% |
| Q3 2018 | -3.99% |
| Q2 2018 | -46.32% |
| Q1 2018 | -64.99% |
| Q4 2017 | 515.71% |
| Q3 2017 | 16.89% |
| Q2 2017 | -51.59% |
| Q1 2017 | 18.58% |
| Q4 2016 | 58.18% |
| Q3 2016 | 33.54% |
| Q2 2016 | -2.44% |
| Q1 2016 | -30.75% |